IMS2186 is an anti-choroidal neovascularization (CNV) agent. IMS2186 arrests the cancer/tumor cell cycle in the G2/M phase, thereby exerting anti-proliferation and anti-angiogenic effects. IMS2186 has no intraocular toxicity and reduces eye leakage and the number of diseased cells.

Physicochemical Properties

Molecular Formula	C18H16O4
Molecular Weight	296.317245483398
Exact Mass	296.105
CAS #	1031206-36-6
PubChem CID	24987039
Appearance	Light yellow to yellow solid powder
LogP	3.367
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	4
Rotatable Bond Count	2
Heavy Atom Count	22
Complexity	444
Defined Atom Stereocenter Count	0
SMILES	CC1=CC2=C(C=C1)OCC(=CC3=CC(=C(C=C3)OC)O)C2=O
InChi Key	BZCADTHMZLYKAR-MDWZMJQESA-N
InChi Code	InChI=1S/C18H16O4/c1-11-3-5-16-14(7-11)18(20)13(10-22-16)8-12-4-6-17(21-2)15(19)9-12/h3-9,19H,10H2,1-2H3/b13-8+
Chemical Name	(3E)-3-[(3-hydroxy-4-methoxyphenyl)methylidene]-6-methylchromen-4-one
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

ln Vitro	Human fibroblasts and human cancer cells proliferate at IMS2186 (0.3-10 μM; 22 h); their corresponding IC50 values are 1.0-3.0 μM and 0.3-3.0 μM[1]. With an IC50 of 0.1-0.3 μM, IMS2186 (0-10 μM; 22 h) suppresses the production of the pro-inflammatory cytokine PGE2/TNF-a in macrophages [1]. With an IC50 of 1 μM, IMS2186 (0.1-10 μM; 1.5 h) similarly prevents macrophage migration [1].
ln Vivo	No ocular toxicity was seen following delivery of IMS2186 (2.5 mg in 0.5 mL; intravitreal injection; single dose) to the eye [1]. IMS2186 (100 μg/eye, i.e. 2.0 μL of 50 μg/μL solution; single dosage) displays anti-aging effects in a vascular model of laser-induced choroidal neovascularization (CNV) [1].
Cell Assay	Cell cycle analysis[1] Cell Types: Cancer H460 cells Tested Concentrations: 3 μM 0.3-1 μM[1]. , 10 μM Incubation Duration: Experimental Results: Demonstrates anti-proliferative activity mediated by arresting the cell cycle at G2/M.
Animal Protocol	Animal/Disease Models: Laser-induced CNV rat model [1] Doses: 100 μg/eye, 50 μg/eye solution 2.0 μL μL Route of Administration: intravitreal injection; single dose Experimental Results: in lesion area measurement, compared with PBS The area has been diminished by 30%.
References	[1]. Falkenstein IA, et al. Toxicity and intraocular properties of a novel long-acting anti-proliferative and anti-angiogenic compound IMS2186. Curr Eye Res. 2008 Jul;33(7):599-609.

Solubility Data

Solubility (In Vitro)

DMSO : ~66.67 mg/mL (~224.99 mM)

Solubility (In Vivo)

Solubility in Formulation 1: 1.25 mg/mL (4.22 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	3.3747 mL	16.8737 mL	33.7473 mL
	5 mM	0.6749 mL	3.3747 mL	6.7495 mL
	10 mM	0.3375 mL	1.6874 mL	3.3747 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.